Cidara Therapeutics Inc.
Cidara Therapeutics, Inc. Approves Reverse Stock Split
Summary
On April 4, 2024, Cidara Therapeutics, Inc. held its 2024 Special Meeting of Stockholders, where stockholders approved a proposal to implement a reverse stock split of the company's common stock in the range of 1-for-10 to 1-for-30, inclusive. The reverse stock split was approved by a significant majority, with 44,612,037 votes in favor, 15,877,556 votes against, and 62,357 abstentions. Additionally, stockholders approved an adjournment of the meeting if necessary to solicit additional proxies.
Profitelligence Alerts
Get alerts for CDTX
Be first to know when Cidara Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Cidara Therapeutics Inc.
Cidara Therapeutics Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives and immunotherapies. Its primary function involves addressing unmet medical needs in the treatment of serious infectious diseases and immune-based conditions. Emphasizing innovation, Cidara Therapeutics is known for its pioneering Cloudbreak platform, which integrates potent drug conjugates designed to address life-threatening bacterial, viral, and fungal infections. The asset prominently impacts the biotechnology and pharmaceutical sectors, endeavoring to transform standard infection treatments with its advanced therapeutic solutions. Cidara's pipeline includes the development of new antifungal agents like rezafungin, aimed at treating invasive fungal infections that significantly affect immunocompromised patients. With its strategic focus, Cidara Therapeutics plays a critical role in the emerging markets of antimicrobial resistance and immunotherapy. Positioned within the healthcare industry, Cidara's contributions hold significant potential to alter existing therapies and specialize in meeting complex medical challenges, reinforcing the broader landscape of pharmaceutical advancements and patient care strategies.
Official SEC Documents
Advertisement